Stock Events

Stock Events

PYC Therapeutics Limited 

0
0
+€0.00+0% 00:00 Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27AugExpected
Q4 2025
Next
-0.04
-0.03
-0.02
-0.02
Expected EPS
-0.018180656274
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PH7.STU. It's not an investment recommendation.
Bitcoin
2
BTC.CRYPTO
Ethereum
2
ETH.CRYPTO
Dogecoin
2
DOGE.CRYPTO
Vanguard Australian Shares Index
2
VAS.AU

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.76B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with PYC's RNA-based therapies.
Ionis Pharmaceuticals
IONS
Mkt Cap13.52B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery, similar to PYC's approach in genetic medicines.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap11.83B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, akin to PYC's strategy.
Sarepta Therapeutics
SRPT
Mkt Cap2.04B
Sarepta Therapeutics is involved in precision genetic medicine, particularly for rare diseases, competing in the same niche as PYC.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.4B
BioMarin Pharmaceutical offers therapies for rare genetic diseases, competing with PYC's focus on rare and serious diseases.
Seres Therapeutics
MCRB
Mkt Cap74.95M
Seres Therapeutics focuses on microbiome therapeutics but is expanding into genetic and RNA therapies, entering PYC's domain.
Editas Medicine
EDIT
Mkt Cap560.14M
Editas Medicine operates in the genome editing space, which is closely related to genetic therapies like those developed by PYC.
CRISPR Therapeutics
CRSP
Mkt Cap5.92B
CRISPR Therapeutics is engaged in gene editing, a competitive field in the broader scope of genetic medicine relevant to PYC's interests.

About

PYC Therapeutics Limited, a development-stage biotechnology company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and VP-002, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for retinal and central nervous system diseases. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Show more...
CEO
Mr. Sahm Nasseri M.B.A., MBA
Country
Australia
ISIN
AU000000PYC7

Listings

OTC Link
US
PYCXF
STU
DE
PH7.STU
MU
DE
PH7.MU
AU
AU
PYC.AU

0 Comments

Share your thoughts

FAQ

What is PYC Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange PYC Therapeutics Limited stocks are traded under the ticker PH7.STU.
When is the next PYC Therapeutics Limited earnings date?▼
PYC Therapeutics Limited is going to release the next earnings report on August 27, 2026.
What were PYC Therapeutics Limited earnings last quarter?▼
PH7.STU earnings for the last quarter are -0.02 EUR per share, whereas the estimation was -0.04 EUR resulting in a +40.24% surprise. The estimated earnings for the next quarter are N/A EUR per share.
In which sector is PYC Therapeutics Limited located?▼
PYC Therapeutics Limited operates in the Health & Wellness sector.
When did PYC Therapeutics Limited complete a stock split?▼
PYC Therapeutics Limited has not had any recent stock splits.
Where is PYC Therapeutics Limited headquartered?▼
PYC Therapeutics Limited is headquartered in Nedlands, Australia.